irf2bp2b Antibody

What is IRF2BP2 and why is it a significant target for antibody-based research?

IRF2BP2 is a transcriptional corepressor that interacts with the interferon regulatory factor-2 (IRF2). In humans, the canonical protein has 587 amino acid residues with a molecular weight of approximately 61 kDa. Its subcellular localization spans both nucleus and cytoplasm, with alternative splicing generating three distinct isoforms. As a member of the IRF2BP protein family, it functions as a transcriptional corepressor in an IRF2-dependent manner, but notably, this repression does not involve histone deacetylase activities .

The protein's significance has grown with recent discoveries linking IRF2BP2 variants to primary antibody deficiency, autoimmunity, and certain cancers, making it a valuable target for immunological and oncological research. Its ubiquitous expression across diverse cell types suggests involvement in multiple signaling pathways, particularly in immune regulation and malignant transformation .

What are the key considerations when selecting an appropriate anti-IRF2BP2 antibody for research?

When selecting an anti-IRF2BP2 antibody, researchers should consider:

• Isoform specificity: Determine which of the three known isoforms your research targets, and select antibodies that can distinguish between them if necessary.

• Species reactivity: Ensure the antibody reacts with your experimental model organism. Available antibodies show reactivity across various species including human, mouse, rat, rabbit, and zebrafish .

• Application compatibility: Verify validation for your specific application such as Western blot (WB), ELISA, immunohistochemistry (IHC), immunoprecipitation (IP), or flow cytometry (FACS) .

• Domain targeting: Consider whether your research questions involve specific domains like the C-terminal RING finger domain or N-terminal zinc finger domain, as these show different cellular behaviors when mutated .

• Clonality: Determine whether polyclonal (broader epitope recognition) or monoclonal (single epitope specificity) antibodies are more appropriate for your experimental design .

• Validation evidence: Review available validation data including Western blot images, citation records, and specific application protocols before selection .

What are the optimal storage and handling conditions for IRF2BP2 antibodies?

For maximum stability and performance of IRF2BP2 antibodies, follow these guidelines:

• Short-term storage: Store at 4°C for active experiments in progress (typically up to two weeks) .

• Long-term storage: Aliquot and store at -20°C to prevent freeze-thaw cycles that degrade antibody quality .

• Formulation: Many commercial IRF2BP2 antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.2 .

• Reconstitution: For lyophilized antibodies, reconstitute with deionized water to the manufacturer's recommended concentration (typically 1 mg/ml) .

• Working dilution: Empirically determine optimal working concentrations for each application; typical starting dilutions are 1:1000 for Western blot .

• Aliquoting: Make small, single-use aliquots to avoid repeated freeze-thaw cycles which significantly reduce antibody performance.

How can IRF2BP2 antibodies be effectively used to study its role in transcriptional regulation networks?

IRF2BP2 antibodies can be strategically employed to investigate transcriptional regulation through several advanced approaches:

• Chromatin Immunoprecipitation (ChIP): Use IRF2BP2 antibodies for ChIP assays to identify genomic binding sites, particularly when investigating its interaction with super-enhancer regions. This approach revealed how IRF2BP2 cooperates with master transcription factors in T-ALL cells to target the enhancer of the RAG1 gene .

• Co-immunoprecipitation (Co-IP): Employ antibodies to pull down IRF2BP2 and associated protein complexes to identify interaction partners involved in transcriptional repression. This is particularly important when investigating how IRF2BP2 interacts with IRF2 and potentially other transcription factors .

• CUT&Tag analysis: Contemporary CUT&Tag approaches using IRF2BP2 antibodies have revealed significant enrichment of master transcription factors (ERG, ELF1, ETS1, RUNX1) in the IRF2BP2 super-enhancer region, providing insights into its regulation .

• Nuclear/cytoplasmic fractionation: Study the subcellular distribution of IRF2BP2 and how it impacts the nuclear translocation of other factors like IRF2 and NFκB1(p50). This has revealed that IRF2BP2 variants impair the nuclear translocation of these factors .

• Dual-luciferase reporter assays: Combine with knockdown/overexpression studies to determine the impact of IRF2BP2 on the transcriptional activity of specific promoters, particularly those involved in immune regulation.

What experimental approaches can distinguish between the three isoforms of IRF2BP2?

Distinguishing between the three isoforms of IRF2BP2 requires specialized experimental approaches:

How can IRF2BP2 antibodies be utilized to investigate its role in immunodeficiency and autoimmune disorders?

Recent research has linked IRF2BP2 variants to primary antibody deficiency and autoimmunity, offering several experimental approaches using antibodies:

• Patient sample analysis: Use immunoblotting with IRF2BP2 antibodies to compare expression levels and post-translational modifications between patient samples and healthy controls .

• Cellular phenotyping: Combine flow cytometry with intracellular staining using IRF2BP2 antibodies to analyze protein expression in specific immune cell subsets from patients with immunodeficiency or autoimmunity.

• Functional reconstitution assays: In cells from patients with IRF2BP2 variants, perform reconstitution experiments with wild-type protein, then use antibodies to verify expression and restoration of normal cellular functions and signaling pathways .

• Signaling pathway analysis: Use IRF2BP2 antibodies in combination with antibodies against key immune signaling molecules (e.g., NFκB components) to track how variants affect critical immune regulatory pathways. Research has shown impaired nuclear translocation of IRF2 and NFκB1 (p50) in cells with IRF2BP2 mutations .

• Animal model validation: In conditional knockout mouse models, use antibodies to confirm the deletion of IRF2BP2 in specific immune cell populations and correlate with phenotypic changes in immune function. Studies have shown that while IRF2BP2 has minimal impact on normal T cell development, its role becomes crucial in pathological conditions .

What are common pitfalls when using IRF2BP2 antibodies in Western blotting and how can they be addressed?

When using IRF2BP2 antibodies for Western blotting, researchers should be aware of these common challenges and solutions:

• Multiple bands: IRF2BP2 can appear as multiple bands due to its three isoforms and post-translational modifications like phosphorylation. Solution: Use positive controls with known isoform expression and phosphatase treatment to determine which bands represent which forms .

• Weak signal: IRF2BP2 may be expressed at relatively low levels in some cell types. Solution: Optimize protein loading (25-50 μg per lane is often effective), use more sensitive detection methods like ECL, and extend exposure time to 5+ seconds as demonstrated in validation studies .

• High background: Non-specific binding can obscure specific signals. Solution: Use optimized blocking conditions (3% nonfat dry milk in TBST has been effective) and dilute primary antibody appropriately (1:1000 dilution has shown good results in validated protocols) .

• Nuclear protein extraction challenges: As IRF2BP2 is primarily nuclear, inadequate nuclear protein extraction can reduce signal. Solution: Use specialized nuclear extraction protocols with protease inhibitors, and verify extraction efficiency with nuclear marker controls.

• Size verification issues: The antibody may detect non-specific proteins of similar molecular weight. Solution: Include knockout/knockdown controls or use recombinant IRF2BP2 as a positive control to confirm band specificity .

How can researchers validate IRF2BP2 antibody specificity for immunofluorescence applications?

Validating IRF2BP2 antibody specificity for immunofluorescence requires systematic controls:

• Knockout/knockdown validation: Compare staining between wild-type cells and those with IRF2BP2 knockdown/knockout to confirm signal specificity.

• Peptide competition assay: Pre-incubate the antibody with blocking peptides containing the epitope to demonstrate specific binding. This approach is particularly useful when non-specific binding is an issue, as it allows comparison between blocked and unblocked antibody staining patterns .

• Subcellular localization verification: Confirm that the staining pattern matches the expected nuclear and cytoplasmic distribution of IRF2BP2. Confocal microscopy studies have shown that wild-type IRF2BP2 exhibits primarily nuclear localization, while variants in the C-terminal RING finger domain show irregular aggregate formation and distribution .

• Multiple antibody validation: Use two or more antibodies targeting different epitopes of IRF2BP2 to confirm that the staining pattern is consistent.

• Recombinant expression control: Overexpress tagged IRF2BP2 (e.g., EGFP-fused) and verify co-localization of the antibody signal with the tag signal.

• Cross-reactivity testing: Test the antibody on cells from different species to ensure specificity for the target species, especially important when working with antibodies claiming multi-species reactivity .

What approaches can address inconsistent results when studying IRF2BP2 in different cell types?

Inconsistent results across cell types may reflect biological variability in IRF2BP2 function or technical challenges:

• Cell type-specific expression levels: Different cell types express varying levels of IRF2BP2 and its isoforms. Solution: Perform quantitative Western blot with loading controls and RT-qPCR to establish baseline expression profiles for each cell type before comparative studies.

• Differential isoform expression: The three isoforms may have different expression patterns across cell types. Solution: Use isoform-specific detection methods and create a cell type-specific isoform expression table to interpret results appropriately.

• Context-dependent protein interactions: IRF2BP2's function may vary based on available interaction partners in different cell types. Solution: Perform co-immunoprecipitation studies to identify cell type-specific interaction networks.

• Stimulus-dependent responses: IRF2BP2 expression and function can change with cellular stimulation. For example, LPS stimulation has been shown to reduce IRF2BP2 mRNA expression in variant-expressing cells compared to wild-type . Solution: Standardize stimulation protocols and include time-course analyses.

• Technical variability in nuclear extraction: As a nuclear protein, extraction efficiency may vary by cell type. Solution: Optimize nuclear extraction protocols specifically for each cell type and include fractionation quality controls.

How have IRF2BP2 antibodies contributed to understanding its role in T-cell acute lymphoblastic leukemia (T-ALL)?

Recent research using IRF2BP2 antibodies has revealed critical insights into T-ALL pathogenesis:

• Super-enhancer regulation: CUT&Tag assays using IRF2BP2 antibodies identified a previously unreported super-enhancer region in T-ALL patient samples and cell lines that drives IRF2BP2 expression. This super-enhancer is regulated by master transcription factors including ERG, ELF1, and ETS1 .

• Essential role in leukemic cell survival: Using IRF2BP2 conditional knockout mouse models followed by antibody validation of deletion, researchers demonstrated that while IRF2BP2 has minimal impact on normal T cell development, it is crucial for T-ALL cell growth and survival both in vitro and in vivo .

• Pathway impact identification: Immunoblotting with IRF2BP2 antibodies helped establish that loss of IRF2BP2 affects the MYC and E2F pathways in T-ALL cells, providing mechanistic insights into how it promotes leukemic cell survival .

• Transcriptional complex formation: Co-immunoprecipitation using IRF2BP2 antibodies revealed that IRF2BP2 cooperates with master transcription factors in T-ALL cells to target the enhancer of the T-ALL susceptibility gene RAG1, modulating its expression .

• Potential therapeutic target validation: The combined findings established IRF2BP2 as a potential new target for therapeutic intervention in T-ALL, as it appears critical for leukemic but not normal T-cell development .

What is known about the mechanistic role of IRF2BP2 variants in primary immunodeficiency disorders?

Recent studies using IRF2BP2 antibodies have elucidated several mechanisms by which variants contribute to immunodeficiency:

• Altered expression and localization: Immunofluorescence and Western blotting with IRF2BP2 antibodies revealed that disease-associated variants show altered IRF2BP2 mRNA and protein expression levels. Specifically, variants in the C-terminal RING finger domain demonstrate irregular aggregate formation and abnormal subcellular distribution compared to wild-type protein .

• Impaired nuclear factor translocation: Immunoblotting showed that IRF2BP2 variants impair the nuclear translocation of both IRF2 and NFκB1 (p50), potentially affecting the expression of genes involved in immune regulation .

• Differential response to immune stimulation: LPS stimulation experiments monitored by RT-qPCR and verified with protein detection showed reduced IRF2BP2 mRNA expression in cells carrying variants compared to wild-type cells, suggesting altered response to immunological challenges .

• Domain-specific effects: Antibody-based studies helped distinguish between variants in the N-terminal zinc finger domain versus the C-terminal RING finger domain, with the latter showing more pronounced effects on protein aggregation and subcellular distribution .

• Hypermorphic variant activity: The novel variants identified appear to be hypermorphic (gain-of-function), as they lead to upregulation of IRF2BP2 and subsequent impairment of IRF2 and NFκB1 nuclear translocation, creating a mechanistic link to the observed immunodeficiency and autoimmunity phenotypes .

How might IRF2BP2 antibodies be utilized in developing new therapeutic approaches for immunodeficiency or cancer?

The emerging role of IRF2BP2 in immunodeficiency and cancer suggests several therapeutic research directions:

• Therapeutic antibody development: Create function-modulating antibodies that could restore normal IRF2BP2 function in cases of gain-of-function mutations, or inhibit aberrant IRF2BP2 activity in contexts where it drives cancer cell survival.

• Biomarker validation: Use IRF2BP2 antibodies to evaluate its potential as a prognostic or predictive biomarker in T-ALL and other cancers, correlating expression levels with treatment response and patient outcomes.

• Drug screening platform development: Create cell-based screening systems with antibody-based readouts that can identify small molecules capable of modulating IRF2BP2 function or expression, particularly in targeting its super-enhancer in T-ALL.

• Combination therapy rationale: Given IRF2BP2's impact on MYC and E2F pathways in T-ALL cells, use antibody-based pathway analysis to identify rational combination therapies targeting multiple nodes in these oncogenic networks .

• Engineered T-cell therapy enhancement: For immunotherapies, explore how modulation of IRF2BP2 might enhance T-cell function without promoting leukemogenesis, potentially improving CAR-T approaches.

What are emerging techniques combining IRF2BP2 antibodies with other molecular tools for comprehensive functional analysis?

Cutting-edge research is integrating IRF2BP2 antibodies with advanced technologies:

• CUT&Tag-seq innovations: Combine IRF2BP2 antibodies with CUT&Tag-seq to map genomic binding sites with high resolution and low background, as demonstrated in recent T-ALL studies identifying super-enhancer regions .

• CRISPR-based genomic screening: Use IRF2BP2 antibodies to validate CRISPR knockout/knockin screens targeting IRF2BP2 regulators or effectors, establishing comprehensive genetic interaction networks.

• Proximity labeling techniques: Implement BioID or APEX2 proximity labeling systems coupled with IRF2BP2 antibodies for validation to map the protein interaction landscape of IRF2BP2 in different cellular contexts.

• Single-cell protein-DNA mapping: Combine single-cell technologies with IRF2BP2 antibodies to understand cell-to-cell variation in IRF2BP2 function and genomic interactions, particularly important in heterogeneous tumor samples.

• Spatial transcriptomics integration: Correlate IRF2BP2 protein localization (via immunofluorescence) with spatial transcriptomics data to understand how its nuclear organization influences gene expression patterns across tissue microenvironments.

• Live-cell antibody-based imaging: Develop cell-permeable antibody fragments or nanobodies against IRF2BP2 for live-cell imaging to track dynamic changes in IRF2BP2 localization and interactions during cell state transitions or therapeutic interventions.